A Decade of Experience Using mTor Inhibitors in Liver Transplantation
Some studies suggest that Sirolimus (SRL) is associated with an increased risk of death in liver transplant recipients compared to treatment with calcineurin inhibitors (CNIs). We compared patients who received SRL or CNI in the first year after liver transplant. Our database included 688 patients...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Journal of Transplantation |
| Online Access: | http://dx.doi.org/10.1155/2011/913094 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832549640354922496 |
|---|---|
| author | Jeffrey Campsen Michael A. Zimmerman Susan Mandell Maria Kaplan Igal Kam |
| author_facet | Jeffrey Campsen Michael A. Zimmerman Susan Mandell Maria Kaplan Igal Kam |
| author_sort | Jeffrey Campsen |
| collection | DOAJ |
| description | Some studies suggest that Sirolimus (SRL) is associated with an increased risk of death in liver transplant recipients compared to treatment with calcineurin inhibitors (CNIs). We compared patients who received SRL or CNI in the first year after liver transplant. Our database included 688 patients who received a liver transplant. The patients were divided into groups. (1) CNI + MPS (mycophenolate sodium) at time of discharge. (2) CNI + MPS at time of discharge; SRL was added within the first 6 months and continued through the first year. (3) CNI + MPS at time of discharge; SRL was added within the first 6 months and discontinued before the first year. (4) SRL as primary immunosuppression. (5) SRL as primary immunosuppression and discontinued before the first year. We used mortality and graft loss as the primary measures of outcome. We also quantified renal function using the change in glomerular filtration rate (GFR), the presence of biopsy proven acute cellular reject (ACR), and steroid-resistant rejection (SRR). There were no significant differences in mortality or graft loss. There was no difference in patient or graft survival. Patients that received SRL as primary immunosuppression had 50% less rejection compared to controls. |
| format | Article |
| id | doaj-art-386217f2f86c47e9987ddbbc101e9cff |
| institution | Kabale University |
| issn | 2090-0007 2090-0015 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Transplantation |
| spelling | doaj-art-386217f2f86c47e9987ddbbc101e9cff2025-02-03T06:10:51ZengWileyJournal of Transplantation2090-00072090-00152011-01-01201110.1155/2011/913094913094A Decade of Experience Using mTor Inhibitors in Liver TransplantationJeffrey Campsen0Michael A. Zimmerman1Susan Mandell2Maria Kaplan3Igal Kam4Division of Transplant Surgery, Department of Surgery, School of Medicine, University of Colorado Denver, Aurora, CO 80045, USADivision of Transplant Surgery, Department of Surgery, School of Medicine, University of Colorado Denver, Aurora, CO 80045, USADivision of Transplant Surgery, Department of Surgery, School of Medicine, University of Colorado Denver, Aurora, CO 80045, USADivision of Transplant Surgery, Department of Surgery, School of Medicine, University of Colorado Denver, Aurora, CO 80045, USADivision of Transplant Surgery, Department of Surgery, School of Medicine, University of Colorado Denver, Aurora, CO 80045, USASome studies suggest that Sirolimus (SRL) is associated with an increased risk of death in liver transplant recipients compared to treatment with calcineurin inhibitors (CNIs). We compared patients who received SRL or CNI in the first year after liver transplant. Our database included 688 patients who received a liver transplant. The patients were divided into groups. (1) CNI + MPS (mycophenolate sodium) at time of discharge. (2) CNI + MPS at time of discharge; SRL was added within the first 6 months and continued through the first year. (3) CNI + MPS at time of discharge; SRL was added within the first 6 months and discontinued before the first year. (4) SRL as primary immunosuppression. (5) SRL as primary immunosuppression and discontinued before the first year. We used mortality and graft loss as the primary measures of outcome. We also quantified renal function using the change in glomerular filtration rate (GFR), the presence of biopsy proven acute cellular reject (ACR), and steroid-resistant rejection (SRR). There were no significant differences in mortality or graft loss. There was no difference in patient or graft survival. Patients that received SRL as primary immunosuppression had 50% less rejection compared to controls.http://dx.doi.org/10.1155/2011/913094 |
| spellingShingle | Jeffrey Campsen Michael A. Zimmerman Susan Mandell Maria Kaplan Igal Kam A Decade of Experience Using mTor Inhibitors in Liver Transplantation Journal of Transplantation |
| title | A Decade of Experience Using mTor Inhibitors in Liver Transplantation |
| title_full | A Decade of Experience Using mTor Inhibitors in Liver Transplantation |
| title_fullStr | A Decade of Experience Using mTor Inhibitors in Liver Transplantation |
| title_full_unstemmed | A Decade of Experience Using mTor Inhibitors in Liver Transplantation |
| title_short | A Decade of Experience Using mTor Inhibitors in Liver Transplantation |
| title_sort | decade of experience using mtor inhibitors in liver transplantation |
| url | http://dx.doi.org/10.1155/2011/913094 |
| work_keys_str_mv | AT jeffreycampsen adecadeofexperienceusingmtorinhibitorsinlivertransplantation AT michaelazimmerman adecadeofexperienceusingmtorinhibitorsinlivertransplantation AT susanmandell adecadeofexperienceusingmtorinhibitorsinlivertransplantation AT mariakaplan adecadeofexperienceusingmtorinhibitorsinlivertransplantation AT igalkam adecadeofexperienceusingmtorinhibitorsinlivertransplantation AT jeffreycampsen decadeofexperienceusingmtorinhibitorsinlivertransplantation AT michaelazimmerman decadeofexperienceusingmtorinhibitorsinlivertransplantation AT susanmandell decadeofexperienceusingmtorinhibitorsinlivertransplantation AT mariakaplan decadeofexperienceusingmtorinhibitorsinlivertransplantation AT igalkam decadeofexperienceusingmtorinhibitorsinlivertransplantation |